Enasidenib: Well-tolerated and May Provide Benefit in R/R AML

Share this content:
Among patients with R/R disease, 19.3% achieved complete remission (CR) and had a median overall survival of 19.7 months.
Among patients with R/R disease, 19.3% achieved complete remission (CR) and had a median overall survival of 19.7 months.

Adult patients with mutant-IDH2 relapsed/refractory (R/R) acute myeloid leukemia (AML) may benefit from continuous daily enasidenib, according to a study published in Blood.1

For this maximum tolerated dose (MTD)-determining phase 1/2 trial (ClinicalTrials.gov Identifier: NCT01915498), researchers assessed the safety and efficacy of enasidenib among 239 patients with R/R AML. In the dose-escalation phase, patients received 5 enasidenib dose levels ranging from 30 mg to 150 mg twice daily, and 8 dose levels once daily ranging from 50 mg to 650 mg. In the expansion phase, patients were separated into 4 arms and received the dose of enasidenib determined in the escalation phase.

A 100 mg once-daily dose was chosen for the expansion phase based on demonstrated efficacy and pharmacokinetic/pharmacodynamic profiles.

Among patients with R/R disease, 19.3% achieved complete remission (CR) and had a median overall survival of 19.7 months. The median overall survival was 9.3 months among all patients with R/R AML.

The overall response rate was 40.3% (95% CI, 33.0%-48.0%), with a median duration of 5.8 months. 

Eighty-two percent of patients had a treatment-related adverse event (AE). The most frequently reported treatment-related grade 3 to 4 AEs were indirect hyperbilirubinemia (12%) and IDH-inhibitor-associated differentiation syndrome (7%).

RELATED: FDA Approves Daunorubicin-Cytarabine Combination for AML Subtypes

Only 5% of patients discontinued therapy as a result of a treatment-related AE.

Reference

  1. Stein EM, Dinardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Aug 10. doi: 10.1182/blood-2017-04-779405 [Epub ahead of print] 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters